Arrhythmia worries lead to revised labeling for Zofran
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline's antiemetic Zofran (ondansetron) and its generic equivalents – drugs used to prevent nausea and vomiting caused by cancer chemotherapy, radiation therapy and surgery – are no longer being recommended for use at the 32mg single intravenous dose after preliminary study results showed that dose may lead to QT interval prolongation, an abnormal electrical activity of the heart, which can result in a potentially fatal arrhythmia, known as torsades de point (TDP).